ContraFect to Present at The MicroCap Conference
September 28 2017 - 7:00AM
ContraFect Corporation (NASDAQ:CFRX), a
biotechnology company focused on the discovery and development of
protein and antibody therapeutics for life-threatening,
drug-resistant infectious diseases, today announced that Steven C.
Gilman, Ph.D., the Company's Chairman and Chief Executive Officer,
will present a corporate overview at The MicroCap Conference on
Thursday, October 5, 2017 at 1:00 PM ET in New York, NY. The focus
of the presentation will be ContraFect's novel approach to the
treatment of antibiotic-resistant infections, including the
Company’s lead lysin, CF-301, currently in a Phase 2 clinical trial
for the treatment of Staphylococcus aureus (Staph aureus)
bacteremia including endocarditis.
About ContraFect:
ContraFect is a biotechnology company focused on discovering and
developing therapeutic protein and antibody products for
life-threatening, drug-resistant infectious diseases, particularly
those treated in hospital settings. An estimated 700,000 deaths
worldwide each year are attributed to antimicrobial-resistant
infections. We intend to address life threatening infections using
our therapeutic product candidates from our lysin and monoclonal
antibody platforms to target conserved regions of either bacteria
or viruses (regions that are not prone to mutation). ContraFect's
initial product candidates include new agents to treat
antibiotic-resistant infections such as MRSA (Methicillin-resistant
Staph aureus) and influenza. ContraFect is also conducting research
focused on the discovery of lysins to target Gram-negative
bacteria.
About CF-301:
CF-301 is a recombinant bacteriophage-derived lysin with potent
bactericidal activity against Staphylococcus aureus (Staph aureus),
a major cause of blood stream infections, or bacteremia. CF-301 has
the potential to be a first-in-class treatment for Staph aureus
bacteremia. It has a novel, rapid, and specific mechanism of
bactericidal action against Staph aureus and therefore should not
impact the body's natural bacterial flora. By targeting a conserved
region of the cell wall that is vital to bacteria, resistance is
unlikely to develop to CF-301. Combinations of CF-301 with standard
of care (SOC) antibiotics significantly increased bacterial killing
and survival in animal models of disease when compared to treatment
with antibiotics or CF-301 alone. In addition, in vitro and in vivo
experiments have shown that CF-301 is highly active against biofilm
infections. CF-301 was licensed from The Rockefeller University and
is being developed at ContraFect. CF-301 is the first lysin
to enter clinical studies in the U.S.
Forward-Looking Statements
This press release contains, and our officers and
representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities
laws. Forward-looking statements can be identified by words
such as “projects,” “may,” “will,” “could,” “would,” “should,”
“believes,” “expects,” “anticipates,” “estimates,” “intends,”
“plans,” “potential,” “promise” or similar references to future
periods. Examples of forward-looking statements in this release
include, without limitation, statements regarding our ability to
discover and develop protein and antibody therapeutics for
life-threatening, drug-resistant infectious diseases, our ability
to address life threatening infections using our therapeutic
product candidates from our lysin and monoclonal antibody platforms
to target conserved regions of either bacteria or viruses, whether
our initial product candidates can treat antibiotic-resistant
infections such as MRSA and influenza, our ability to discover new
lysins targeting Gram-negative bacteria, and the potential for
CF-301 to be a first-in-class treatment for Staph aureus
bacteremia. Forward-looking statements are statements that are not
historical facts, nor assurances of future performance. Instead,
they are based on ContraFect’s current beliefs, expectations and
assumptions regarding the future of its business, future plans,
strategies, projections, anticipated events and trends, the economy
and other future conditions. Because forward-looking statements
relate to the future, they are subject to inherent risks,
uncertainties and changes in circumstances that are difficult to
predict and many of which are beyond ContraFect’s control,
including those detailed in ContraFect's filings with the
Securities and Exchange Commission. Actual results may differ
from those set forth in the forward-looking statements. Important
factors that could cause actual results to differ include, among
others, our ability to develop treatments for drug-resistant
infectious diseases. Any forward-looking statement made by
ContraFect in this press release is based only on information
currently available and speaks only as of the date on which it is
made. Except as required by applicable law, ContraFect expressly
disclaims any obligations to publicly update any forward-looking
statements, whether written or oral, that may be made from time to
time, whether as a result of new information, future developments
or otherwise.
Investor Relations Contact
Paul Boni
ContraFect Corporation
Tel: 914-207-2300
Email: pboni@contrafect.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Apr 2024 to May 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From May 2023 to May 2024